Trial Profile
Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Tolinapant (Primary)
- Indications Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; Carcinoma; Cervical cancer; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Extranodal NK-T-cell lymphoma; Head and neck cancer; Lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; Sezary syndrome; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Astex Pharmaceuticals
- 03 Aug 2023 Planned End Date changed from 1 May 2023 to 1 Oct 2024.
- 03 Aug 2023 Planned primary completion date changed from 1 May 2023 to 1 Oct 2024.
- 09 Aug 2022 Planned End Date changed from 1 May 2022 to 1 May 2023.